Safety and effectiveness of rapid-acting intra-muscular olanzapine for agitation associated with schizophrenia - Japan postmarketing surveillance study.

Katagiri, Hideaki; Taketsuna, Masanori; Kondo, Shinpei; Kajimoto, Kenta; Aoi, Etsuko; Tanji, Yuka

Katagiri, Hideaki; Taketsuna, Masanori; Kondo, Shinpei; Kajimoto, Kenta; Aoi, Etsuko; Tanji, Yuka.

Afiliación

Katagiri H; Bio Medicine.
Taketsuna M; Statistical Sciences.
Kondo S; Post Marketing Study Management.
Kajimoto K; Scientific Communications, Medicines Development Unit Japan.
Aoi E; Global Patient Safety Japan, Quality and Patient Safety, Eli Lilly Japan K.K., Kobe, Japan.
Tanji Y; Bio Medicine.

Neuropsychiatr Dis Treat ; 14: 265-272, 2018.

Article en En | MEDLINE | ID: mdl-29391799

Palabras clave

Japanese; PANSS-EC; agitation; postmarketing surveillance study; rapid-acting intramuscular olanzapine; schizophrenia

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Risk_factors_studies / Screening_studies Idioma: En Revista: Neuropsychiatr Dis Treat Año: 2018 Tipo del documento: Article Pais de publicación: Nueva Zelanda

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google